The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice
Open accessAbstract
Glyburide's pharmacokinetics (PK) and pharmacodynamics have not been studied in women with gestational diabetes mellitus (GDM). The objective of this study was to assess steady-state PK of glyburide, as well as insulin sensitivity, beta-cell responsivity, and overall disposition indices after a mixed-meal tolerance test (MMTT) in women with GDM (n = 40), nonpregnant women with type 2 diabetes mellitus (T2DM) (n = 26), and healthy pregnant women (n = 40, MMTT only). At equivalent doses, glyburide plasma concentrations were approximately 50% lower in pregnant women than in nonpregnant subjects. The average umbilical cord/maternal plasma glyburide concentration ratio at the time of delivery was 0.7 +/- 0.4. Insulin sensitivity was approximately fivefold lower in women with GDM as compared with healthy pregnant women. Despite comparable beta-cell responsivity indices, the average beta-cell function corrected for insulin resistance was more than 3.5-fold lower in women with glyburide-treated GDM than in healthy pregnant women. Women with GDM in whom glyburide treatment has failed may benefit from alternative medication or dosage escalation; however, fetal safety should be kept in mind.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, in separate RCTs, glyburide and metformin failed to provide adequate glycemic outcomes in 23% and 25-28% of participants with GDM, respectively (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sulfonylureas are known to cross the placenta and have been associated with increased neonatal hypoglycemia.”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Concentrations of glyburide in umbilical cord plasma are approximately 50-70% of maternal levels (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [76]
In the citing paper
“In pregnant women taking glyburide, the umbilical cord glyburide concentration is undetectable (90, 173–176) or, at most, very low (177).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Criteria for screening tests for gestational diabetes
Carpenter, M. W., & Coustan, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90349-0 · Cited by 1,924
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,052
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women
Catalano, P. M., Tyzbir, E. D., Roman, N. M., Amini, S. B., & Sims, E. A. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90012-g · Cited by 709
Catalano, P. M., Huston, L., Amini, S. B., & Kalhan, S. C. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70662-9 · Cited by 680
de Veciana, M., Major, C. A., Morgan, M. A., Asrat, T., Toohey, J. S., Lien, J. M., & Evans, A. T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331901 · Cited by 666
Buchanan, T. A., Metzger, B. E., Freinkel, N., & Bergman, R. N. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)91306-w · Cited by 427
Flagged first, then by citations
1 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–101 of 101
Advances in Oral Anti‐Diabetes Drugs in Pregnancy
Mukerji, G., & Feig, D. S. (2017) · A Practical Manual of Diabetes in Pregnancy · doi:10.1002/9781119043805.ch15 · Cited by 2
Metadata
- Authors
- Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., Kelly, E., Blough, D., Cobelli, C., Ahmed, M., Snodgrass, W., Carr, D., Easterling, T., & Vicini, P.
- Affiliations
- University of Washington (US)
- The University of Texas Medical Branch at Galveston (US)
- MedStar Washington Hospital Center (US)
- University of Padua (IT)
- Pfizer (United States) (US)
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-03-18
- Volume
- 85
- Issue
- 6
- Pages
- 607-614
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- PMC
- PMC2684566
- OpenAlex
- W1964571629
- Cited by
- 252
- References
- 52
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 8 · 2023: 11 · 2022: 9 · 2021: 32 · 2020: 12 · 2019: 13 · 2018: 16 · 2017: 13 · 2016: 12 · 2015: 21 · 2014: 19 · 2013: 18 · 2012: 16
- FWCI
- 19.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- University of Pittsburgh
- National Institutes of Health (UL1TR000423, UL1TR000005)
- National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
- National Center for Research Resources (M01RR023942, M01-RR 00037, UL1RR025014, M01RR020359, M01RR000037)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10HD047891, U10HD047892, U10HD047890, U10HD047905)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- gestational diabetes mellitus, glibenclamide, pharmacokinetics, insulin sensitivity, beta-cell function, insulin resistance, mixed meal tolerance test, type 2 diabetes, dose escalation, fetal safety
- MeSH terms
- Adult, Aryl Hydrocarbon Hydroxylases, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Fetal Blood, Glyburide, Humans, Hypoglycemic Agents, Insulin Resistance, Metabolic Clearance Rate, Monte Carlo Method, Pregnancy, Pregnancy Trimester, Third, Diabetes, Gestational, Area Under Curve, Insulin-Secreting Cells, Cytochrome P-450 CYP2C9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
